Inve India ▾

Sudarshan Pharma Industries share price & results

SUDARSHAN PHARMA INDUSTRIES LIMITED· Chemicals· Commodities

Results to
Jun 2026
Ownership as of
Sept 2026

Mumbai-based specialty chemicals and pharmaceutical company manufacturing/importing API intermediates and bulk drugs, and trading finished formulations and branded generics

Company research is public. Sign in to keep your own companies, notes and cases.

Reported

The figures, each with its period

Each figure keeps its basis and period; nothing is filled in.

MetricValueChangeBasisPeriodNote
Revenue174 ₹ crore+20.1% YoYQuarterly, as filedQuarter to Jun 2026Revenue from operations as filed.
Operating margin9.1 %+1.5 pts YoYOperating profit / revenueQuarter to Jun 2026For the quarter; a change is in percentage points.
Net profit5.6 ₹ crore+41.7% YoYQuarterly, as filedQuarter to Jun 2026Profit after tax as filed.
Return on equity17.57 %+1.2 ptsFY Mar 2026 vs FY Mar 2025Trailing twelve monthsTTM to Jun 2026Adjusted profit attributable to owners ÷ average owners’ equity.
Free cash flow margin-9.96 %−3.4 ptsFY Mar 2026 vs FY Mar 2025Fiscal yearFY ending Mar 2026(Operating cash flow − fixed-asset purchases + disposals) ÷ revenue.
Revenue growth (YoY)32.87 %+30.4 ptsFY Mar 2026 vs FY Mar 2025Trailing twelve monthsTTM to Jun 2026Revenue change against the same period one year earlier.

Source: Inve data from filed results; ratios from the Screener-verified panel · to Jun 2026

Price

₹34.98 +11.22% · +₹3.53

Last close 27 Oct 2026 · NSE · INR · Source: Inve

Performance +45.4% 1Y

₹20.0₹25.0₹30.0₹35.0₹40.0Oct 25Dec 25Jan 26Mar 26Apr 26Jun 26Jul 26Sept 26Oct 26

1Y: ₹24.06 on 24 Oct 2025 → ₹34.98. High ₹42.31 (21 Jul 2026), low ₹19.23 (27 Jan 2026).

Previous close
₹31.45
Market cap
₹880 Cr
52-week range
₹19.23 – ₹42.31
One year
+51.36%
Price to earnings (TTM to Jun 2026)
35.02×
Return on equity (TTM to Jun 2026)
17.57%

Overview

Symbol
NSE:SUDARSHAN
Sector
Chemicals
Industry
Commodities
Exchange
NSE
Currency
INR

What SUDARSHAN PHARMA INDUSTRIES LIMITED does

Based on the company's own presentations, annual report and earnings calls.

Sudarshan Pharma Industries manufactures and sources specialty chemicals, API intermediates and active pharmaceutical ingredients, which it upward-integrates into finished pharmaceutical formulations and branded generic drugs. It operates manufacturing units at Palghar (Maharashtra), Jejuri and Hyderabad (Telangana), the last GMP- and ISO 9001:2015-certified for API/intermediate manufacturing. The group also holds several subsidiaries covering specialty chemical trading (dyestuffs, pigments, solvents), oncology API intermediates, and medical-device consumables (sutures, meshes, catheters), and exports its products to over 10 countries.

Segments

  • Chemical raw materials for pharmaceuticals
  • Intermediates for API
  • API manufacturing and import
  • Finished formulation and F&O R&D
  • Branded generics
Manufacturing facilities
3 (Palghar & Jejuri, Maharashtra; Hyderabad, Telangana)
Export presence
10+ countries
Pharma product portfolio
96 products (56 registered under "R" trademark)
Subsidiaries
7 (India, Singapore, Dubai)
Palghar plant - approved products
50 (domestic & international)
Palghar oral-liquid production capacity
2,000 litres/shift, scalable to 6,000 litres across two shifts
Founded 2008Headquarters Borivali (West), Mumbai, Maharashtra Company website

Your own record

Start an Inve Case for SUDARSHAN PHARMA INDUSTRIES LIMITED

Free account: one company. Everything above stays public.

Write why you follow SUDARSHAN PHARMA INDUSTRIES LIMITED and the condition you want checked. Inve compares your numeric conditions with available results and management guidance; your own conditions remain yours to review.

What an account adds

Keep reading

Other Chemicals companies

All Chemicals companies → · Chemicals earnings growth →

Learn to analyse SUDARSHAN PHARMA INDUSTRIES LIMITED

Guides on how to read this kind of business and the numbers that matter.